Rhumbline Advisers Pacira Bio Sciences, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 161,268 shares of PCRX stock, worth $2.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

161,268

Previous 159,467 1.13%

Holding current value

$2.68 Million

Previous $4.56 Million 46.78%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$11.7 - $28.46 $21,071 - $51,256	1,801 Added 1.13%	161,268 $2.43 Million
Q2 2024 Aug 01, 2024	BUY	$25.5 - $31.51 $251,659 - $310,972	9,869 Added 6.6%	159,467 $4.56 Million
Q1 2024 May 09, 2024	BUY	$27.7 - $35.48 $19,196 - $24,587	693 Added 0.47%	149,598 $4.37 Million
Q4 2023 Feb 08, 2024	BUY	$26.32 - $34.31 $204,822 - $267,000	7,782 Added 5.51%	148,905 $5.02 Million
Q3 2023 Nov 09, 2023	BUY	$30.68 - $40.09 $32,950 - $43,056	1,074 Added 0.77%	141,123 $4.33 Million
Q2 2023 Aug 08, 2023	BUY	$36.12 - $47.5 $105,831 - $139,175	2,930 Added 2.14%	140,049 $5.61 Million
Q1 2023 May 11, 2023	BUY	$35.53 - $43.38 $233,645 - $285,266	6,576 Added 5.04%	137,119 $5.6 Million
Q4 2022 Feb 14, 2023	SELL	$38.19 - $57.45 $14,474 - $21,773	-379 Reduced 0.29%	130,543 $5.04 Million
Q3 2022 Nov 10, 2022	BUY	$51.24 - $58.89 $270,905 - $311,351	5,287 Added 4.21%	130,922 $6.96 Million
Q2 2022 Aug 11, 2022	BUY	$51.49 - $81.64 $443,998 - $703,981	8,623 Added 7.37%	125,635 $7.33 Million
Q1 2022 May 12, 2022	BUY	$60.03 - $76.49 $395,297 - $503,686	6,585 Added 5.96%	117,012 $8.93 Million
Q4 2021 Feb 10, 2022	BUY	$47.97 - $62.21 $54,206 - $70,297	1,130 Added 1.03%	110,427 $6.64 Million
Q3 2021 Nov 12, 2021	SELL	$54.64 - $61.3 $833,314 - $934,886	-15,251 Reduced 12.25%	109,297 $6.12 Million
Q2 2021 Aug 05, 2021	SELL	$59.18 - $69.99 $85,633 - $101,275	-1,447 Reduced 1.15%	124,548 $7.56 Million
Q1 2021 May 06, 2021	BUY	$59.31 - $78.82 $19,216 - $25,537	324 Added 0.26%	125,995 $8.83 Million
Q4 2020 Feb 10, 2021	BUY	$50.47 - $66.26 $331,133 - $434,731	6,561 Added 5.51%	125,671 $7.52 Million
Q3 2020 Nov 12, 2020	SELL	$51.97 - $63.0 $853,555 - $1.03 Million	-16,424 Reduced 12.12%	119,110 $7.16 Million
Q2 2020 Aug 13, 2020	SELL	$30.8 - $52.47 $170,170 - $289,896	-5,525 Reduced 3.92%	135,534 $7.11 Million
Q1 2020 May 06, 2020	BUY	$28.4 - $50.7 $24,395 - $43,551	859 Added 0.61%	141,059 $4.73 Million
Q4 2019 Feb 05, 2020	BUY	$36.31 - $46.83 $460,556 - $593,991	12,684 Added 9.95%	140,200 $6.35 Million
Q3 2019 Oct 23, 2019	BUY	$35.66 - $44.99 $2.47 Million - $3.12 Million	69,364 Added 119.28%	127,516 $4.86 Million
Q2 2019 Aug 14, 2019	BUY	$36.57 - $47.97 $132,639 - $173,987	3,627 Added 6.65%	58,152 $2.53 Million
Q1 2019 May 01, 2019	SELL	$36.47 - $42.17 $4,522 - $5,229	-124 Reduced 0.23%	54,525 $2.08 Million
Q4 2018 Jan 31, 2019	BUY	$41.31 - $52.16 $712,927 - $900,177	17,258 Added 46.16%	54,649 $2.35 Million
Q3 2018 Nov 07, 2018	SELL	$32.85 - $52.0 $82,322 - $130,312	-2,506 Reduced 6.28%	37,391 $1.84 Million
Q2 2018 Aug 06, 2018	BUY	$27.5 - $39.8 $36,712 - $53,132	1,335 Added 3.46%	39,897 $1.28 Million
Q1 2018 May 02, 2018	SELL	$29.98 - $46.35 $30,879 - $47,740	-1,030 Reduced 2.6%	38,562 $1.2 Million
Q4 2017 Feb 09, 2018	SELL	$31.85 - $46.95 $337,195 - $497,059	-10,587 Reduced 21.1%	39,592 $1.81 Million
Q3 2017 Nov 06, 2017	BUY	$35.7 - $39.5 $1.79 Million - $1.98 Million	50,179	50,179 $1.88 Million

Others Institutions Holding PCRX

# of Institutions

264

Shares Held

50.6M

Call Options Held

429K

Put Options Held

391K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $763M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Pacira Bio Sciences, Inc. Transaction History